Advertisement
Screener

OCUGEN, INC. (OCGN) Graph

OCGN Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $1.49M; Cost of revenue (m); Research and development $10.69M; Operating expenses $17.93M.
  • 2026-03-31: Revenue $1.53M; Cost of revenue (m); Research and development $11.26M; Operating expenses $19.37M.
  • 2025-12-31: Revenue -$193.00K*; Cost of revenue (m); Research and development $10.67M*; Operating expenses $16.80M*.
  • 2025-09-30: Revenue $1.75M; Cost of revenue (m); Research and development $11.15M; Operating expenses $19.38M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OCGN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$1.49MOperating expenses$17.93MOperating income-$16.44MOther income, net-$78.00KResearch & development$10.69M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$1.49M(m)$10.69M$17.93M(m)-$24.88M
2026-03-31$1.53M(m)$11.26M$19.37M(m)-$19.18M
2025-12-31-$193.00K*(m)$10.67M*$16.80M*(m)-$17.86M*
2025-09-30$1.75M(m)$11.15M$19.38M(m)-$20.05M
2025-06-30$1.37M(m)$8.40M$15.17M(m)-$14.74M
2025-03-31$1.48M(m)$9.53M$15.98M(m)-$15.35M
2024-09-30$1.14M(m)$8.11M$14.39M(m)-$12.97M
2024-06-30$1.14M(m)$8.90M$16.59M(m)-$15.28M
2024-03-31$1.01M(m)$6.83M$13.23M(m)-$11.92M
2023-09-30$3.70M(m)(m)$16.13M(m)-$11.72M
2023-06-30$485.00K(m)(m)$24.02M(m)-$23.07M
2023-03-31$443.00K(m)(m)$18.48M(m)-$17.33M
2022-09-30$466.00K(m)(m)$25.58M$0.00-$23.91M
2022-06-30$643.00K(m)(m)$22.22M(m)-$21.48M
2022-03-31$500.00K(m)(m)$19.53M(m)-$19.02M
2021-12-31$0.00*(m)(m)(m)(m)(m)
2021-09-30$0.00(m)(m)$10.79M-$52.00K-$10.76M
2021-06-30$0.00(m)(m)$25.61M(m)-$25.95M
2021-03-31(m)(m)(m)$7.06M(m)-$7.08M
2020-09-30$0.00(m)(m)$10.18M$0.00-$10.47M
2020-06-30$43.00K(m)(m)$3.41M(m)-$3.61M
2020-03-31(m)(m)$1.65M$3.93M(m)-$3.94M
2019-12-31(m)(m)$1.75M*(m)(m)(m)
2019-09-30$0.00(m)$1.31M$2.71M(m)-$22.77M
2019-06-30$0.00(m)$1.24M$2.33M(m)-$3.54M
2019-03-31$0.00$900.00K$3.79M$4.84M$0.00-$6.31M
2018-12-31$0.00*(m)(m)(m)(m)(m)
2018-09-30$0.00(m)$1.56M$2.40M(m)-$1.93M
2018-06-30$0.00(m)$2.83M$4.05M(m)-$5.29M
2018-03-31$0.00(m)$3.29M$6.09M$0.00-$5.04M
2017-09-30$0.00(m)$3.49M$5.71M(m)-$6.00M
2017-06-30$0.00(m)$4.21M$6.37M(m)-$6.54M
2017-03-31$0.00(m)$4.50M$6.83M$0.00-$7.08M
2016-09-30$0.00(m)$4.88M$6.65M(m)-$9.31M
2016-06-30$0.00(m)$5.79M$7.96M(m)-$8.04M
2016-03-31$0.00(m)$5.59M$7.80M(m)-$7.92M
2015-09-30$0.00(m)$5.85M$8.04M(m)-$8.08M
2015-06-30$0.00(m)$5.86M$7.59M(m)-$7.63M
2015-03-31$0.00(m)$5.76M$7.87M(m)-$7.96M
2014-09-30(m)(m)$13.24M$14.94M(m)-$11.97M
2014-06-30(m)(m)$4.67M$6.01M(m)-$8.30M
2014-03-31(m)(m)-$3.37M-$5.17M(m)-$3.44M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$3.02M(m)$21.95M$37.30M(m)-$44.05M
2025-06-30$2.85M(m)$17.93M$31.15M(m)-$30.09M
2024-06-30$2.15M(m)$15.73M$29.82M(m)-$27.20M
2023-06-30$928.00K(m)(m)$42.50M(m)-$40.39M
2022-06-30$1.14M(m)(m)$41.75M(m)-$40.50M
2021-06-30$0.00(m)(m)$32.67M(m)-$33.03M
2020-06-30$43.00K(m)(m)$7.34M(m)-$7.56M
2019-06-30$0.00$900.00K$5.03M$7.17M$0.00-$9.85M
2018-06-30$0.00(m)$5.84M$8.05M$0.00-$10.33M
2017-06-30$0.00(m)$8.71M$13.20M$0.00-$13.62M
2016-06-30$0.00(m)$11.38M$15.75M(m)-$15.96M
2015-06-30$0.00(m)$11.62M$15.47M(m)-$15.60M
2014-06-30(m)(m)$8.04M$11.18M(m)-$11.74M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$4.61M$29.08M$50.53M(m)-$50.14M
2024-09-30$3.29M$23.84M$44.21M(m)-$40.17M
2023-09-30$4.63M(m)$58.63M(m)-$52.11M
2022-09-30$1.61M(m)$67.33M$0.00-$64.41M
2021-09-30$0.00(m)$43.46M-$52.00K-$43.78M
2020-09-30$43.00K(m)$17.52M$0.00-$18.03M
2019-09-30$0.00$6.34M$9.88M(m)-$32.62M
2018-09-30$0.00$7.41M$10.45M$0.00-$12.26M
2017-09-30$0.00$12.20M$18.92M$0.00-$19.62M
2016-09-30$0.00$16.26M$22.40M(m)-$25.27M
2015-09-30$0.00$17.47M$23.50M(m)-$23.68M
2014-09-30(m)$21.28M$26.12M(m)-$23.71M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$4.41M$39.75M$67.33M$0.00-$68.00M
2024-12-31$4.05M$32.13M$58.81M$0.00-$54.00M
2023-12-31$6.04M$39.57M$71.57M$0.00-$63.00M
2022-12-31$2.49M(m)$91.56M$0.00-$86.80M
2021-12-31$0.00(m)$58.03M-$52.00K-$58.37M
2020-12-31$43.00K(m)$21.33M$0.00-$21.82M
2019-12-31$0.00$8.09M$14.16M$0.00-$20.24M
2018-12-31$0.00$10.32M$16.14M(m)-$18.22M
2017-12-31$0.00$15.57M$24.95M(m)-$26.41M
2016-12-31$0.00$21.58M$30.31M(m)-$16.21M
2015-12-31$0.00$23.24M$31.82M(m)-$32.02M
2014-12-31$0.00$26.04M$32.66M(m)-$22.79M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B